Accesso libero

Completely resected stage III melanoma controversy - 15 years of national tertiary centre experience

INFORMAZIONI SU QUESTO ARTICOLO

Cita

Figure 1

Overall survival (OS) of groups with completion lymph nodes dissection (CLND), synchronous lymph node metastasis (SLNM), metachronous lymph node metastasis (MLNM), unknown primary site metastases (UPM).
Overall survival (OS) of groups with completion lymph nodes dissection (CLND), synchronous lymph node metastasis (SLNM), metachronous lymph node metastasis (MLNM), unknown primary site metastases (UPM).

Figure 2

Overall survival (OS) according to sentinel lymph node (SLN) tumour burden.
Overall survival (OS) according to sentinel lymph node (SLN) tumour burden.

Demographics of sentinel lymph node biopsy (SLNB) group

Negative SLN No. (%)Positive SLN No. (%)Unfound SLN No. (%)All SLNB No. (%)
    Number of patients1837(75.7)519 (21.4)70 (2.9)2426 (100.0)
    Tumour site
          Head174 (9.5)34 (6.6)21 (30.0)229 (9.4)
          Neck30 (1.6)6 (1.2)7 (10.0)43 (1.8)
          Trunk857 (46.7)268 (51.6)30 (42.9)1155 (47.6)
          Limbs776 (42.2)211 (40.7)12 (17.1)999 (41.2)
    Breslow thickness (mm)
           < 1.5757 (41.2)67 (12.7)24 (32.9)848 (34.8)
             1.5–3.5735 (40.0)226 (43.5)26 (37.1)987 (40.7)
            3.5323 (17.6)224 (43.2)20 (28.6)567 (23.4)
            Unknown20 (1.1)3 (0.6)1 (1.4)24 (1.0)
    Ulceration
          Yes554 (30.2)234 (45.1)40 (57.1)828 (34.1)
          No1054 (57.4)232 (44.7)22 (31.4)1308 (53.9)
          Unknown229 (12.5)53 (10.2)8 (11.4)290 (12.0)
    Tumour subtype
          SSM260 (14.2)62 (11.9)9 (12.9)331 (13.6)
          NM277 (15.1)129 (24.9)10 (14.3)416 (17.1)
          LMM14 (0.8)1 (0.2)1 (1.4)16 (0.7)
          ALM29 (1.6)10 (1.9)0 (0.0)39 (1.6)
          Other105 (5.7)25 (4.8)2 (2.9)132 (5.4)
            Unknown1152 (62.7)292 (56.3)48 (68.6)1492 (61.5)

Demographics of the four groups with lymph node dissection

CLND No. (%)MLNM No. (%)SLNM No. (%)UPM No. (%)p
    Number of patients455 (57.7)121 (15.3)149 (18.9)64 (8.1)
    Age (years)0.005
          Mean56605958
          Median56646161
    Gender0.198
          F206 (45.3)63 (52.1)65 (43.6)23 (36.0)
          M249 (54.7)58 (47.9)84 (56.4)41 (64.0)
    Primary tumour site0.254
        Head29 (6.4)16 (13.2)25 (16.8)-
        Neck5 (1.1)4 (3.3)2 (1.3)-
        Trunk235 (51.6)48 (39.7)64 (43.0)-
        Limbs186 (40.9)53 (43.8)58 (39.0)-
    Breslow thickness (mm)<0.001
        Mean ± SD3.9 ± 0.13.5 ± 0.38.5 ± 0.8-
        Median3.02.66.0-
        < 1.560 (13.2)28 (23.1)12 (8.1)-
        1.5–3.5202 (44.4)54 (44.6)21 (14.1)-
        > 3.5190 (41.8)35 (28.9)105 (70.5)-
        Unknown3 (0.7)4 (3.3)11 (7.4)-
    Clark level<0.001
          II2 (0.4)1 (0.8)1 (0.7)-
           III87 (19.1)32 (26.4)16 (10.7)-
           IV234 (51.4)50 (41.3)63 (42.3)-
           V41 (9.0)7 (5.8)33 (22.1)-
           Unknown91 (20.0)31 (25.6)36 (24.2)-
    Ulceration
        Present197 (43.4)47 (38.8)91 (61.1)-<0.001
        Absent213 (46.8)52 (43.0)18 (12.1)-
        Unknown45 (9.9)22 (18.2)40 (26.8)-
    Number of positive nodes<0.001
        Mean ± S.D.1.6 ± 1.83.3 ± 4.04.3 ± 5.44.5 ± 7.0
        Median1222
    Diameter of the largest lymph node metastases (mm)<0.001
        Mean ± S.D.3.5 ± 5.735.3 ± 30.720.8 ± 14.246.0 ± 27.2
            Median1.4281647
eISSN:
1581-3207
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology